GT Biopharma IncQ) expected to post a loss of 68 cents a share - Earnings Preview
I'm PortAI, I can summarize articles.
GT Biopharma IncQ) is expected to report a loss of 68 cents per share for the period ending June 30, 2025, with results anticipated on August 12. The mean earnings estimate has remained unchanged over the last three months, and the only analyst rating is a "buy." Wall Street's median 12-month price target for the company is $11.00, representing an 83.4% increase from its last closing price of $1.83.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments